glp 1 agonists quizlet The GLP-1 and Obesity: How Diabetes Drugs are Changing Non-Diabetic Lives — tl;dr pharmacy The Unstoppable Rise of GLP-1

Description

Exposures Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 January 2007 and 31 December 2020 and the second composed of patients who started and continued on GLP-1 receptor agonists or SGLT-2 inhibitors between 1 January 1 2013 and 31 December 2020

This supports that pharmacies are permitted to compound GLP-1 drugs under section 503A of the Act, provided they adhere to specific conditions outlined by the FDA

Adolescents with obesity prescribed a GLP-1 receptor agonist are less likely to have suicidal ideation or a suicide attempt than those with obesity treated with lifestyle intervention, according to new data

GLP-1s may help reduce alcohol intake among adults with overweight or obesity, according to data presented at the European Congress on Obesity

Those with obesity might have other serious chronic health conditions, including diabetes and high blood pressure, which are leading risk factors for heart disease and stroke